Market research
CORT Corcept Therapeutics Incorporated
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- P/E ratio
- 271.67
- Analyst target
- 141
- Dividend yield
- Not available
- Beta
- 0.46
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US2183521028
- P/E ratio
- 271.67
- Analyst target
- 141
- Dividend yield
- Not available
- Beta
- 0.46
About
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CORT discussion.
5 years, 4 months ago
Corcept Therapeutics Incorporated is currently in a long term downtrend where the price is trading 5.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.5.
Corcept Therapeutics Incorporated's total revenue sank by 2.5% to $86M since the same quarter in the previous year.
Its net income has dropped by 11.5% to $26M since the same quarter in the previous year.
Finally, its free cash flow fell by 28.3% to $35M since the same quarter in the previous year.
Based on the above factors, Corcept Therapeutics Incorporated gets an overall score of 1/5.